Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: Machine-learning screening selected CRNDE, LINC00665 and NEAT1 to form an EMT-related lncRNA signature; the source analyzes TCGA LGG (475), then CGGA cohorts (170 and 420) for prognostic and clinicomolecular replication. Drug/immune response findings are computational response estimates, not demonstrated treatment benefit.
Technology: Machine-learning screening selected CRNDE, LINC00665 and NEAT1 to form an EMT-related lncRNA signature.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Machine-learning screening selected CRNDE, LINC00665 and NEAT1 to form an EMT-related lncRNA signature.
- Limitation / still unknown
- Drug/immune response findings are computational response estimates, not demonstrated treatment benefit.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2022.942966/full · https://pubmed.ncbi.nlm.nih.gov/36090045/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.